Viral hepatitis C

Lancet

Volumn 362, Issue 9401, 2003, Pages 2095-2100

  Poynard, Thierry ^a,c   Yuen, Man Fung ^b   Ratziu, Vlad ^a   Lung Lai, Ching ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; INTERFERON; NEVIRAPINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; STAVUDINE;

AGITATED DEPRESSION; ALOPECIA AREATA; ANOREXIA NERVOSA; BLOOD TRANSFUSION; CHRONICITY; CLINICAL FEATURE; COMORBIDITY; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DRUG CONTRAINDICATION; DRUG ERUPTION; DYSPNEA; ERADICATION THERAPY; FLU LIKE SYNDROME; GENOTYPE ENVIRONMENT INTERACTION; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HYPOTHYROIDISM; INFECTION RATE; INSOMNIA; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER CARCINOMA; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REFRACTORY ANEMIA; RELAPSE; RHINOPHARYNGITIS; RNA ANALYSIS; SEROPREVALENCE; SEROTYPE; SEXUAL BEHAVIOR; SUICIDE ATTEMPT; TERATOGENESIS; VIRUS TRANSMISSION;

EID: 0346157289     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)15109-4     Document Type: Conference Paper

References (75)

1. Lauer G., Walker B.D. Hepatitis C virus infection. N Engl J Med. 345:2001;41-52.
2. World Health Report WHO. Annex table 2: deaths by cause, sex and mortality stratum in WHO regions, estimates for 2001. www.who.int/entity/whr/ 2002/en/whr2002_annex2. pdf (accessed Dec. 1:2002;2003.
3. Lai C.L., Ratziu V., Yuen M-F, Poynard T. Viral hepatitis B. Lancet. 362:2003;2089-2094.
4. El-Serag H.B. Hepatocellular carcinoma: an epidemiological view. J Clin Gastroenterol. 35:(suppl):2002;S72-S78.
5. El-Serag H.B., Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 34:1999;745-750.
6. Deuffic S., Buffat L., Poynard T., Valleron A.J. Modeling the hepatitis C virus epidemic in France. Hepatology. 29:1999;1596-1601.
7. Deuffic S., Poynard T., Valleron A.J. Correlation between HCV prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat. 6:1999;411-413.
8. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol (in press).
9. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, through 1994. N Engl J Med ; 341. 1999:1988;556-562.
10. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
11. Mathurin P., Moussalli J., Cadranel J.F., et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology. 27:1998;868-872.
12. Poynard T., Ratziu V., Benhamou Y., Di Martino V.D., Bedossa P., Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis. 20:2000;47-55.
13. Paradis V., Mathurin P., Laurent A., et al. Histological features predictive of liver fibrosis in chronic hepatitis C infection. J Clin Pathol. 49:1996;998-1004.
14. Yano M., Kumada H., Kage M., et al. The long term pathological evolution of chronic hepatitis C. Hepatology. 23:1996;1334-1340.
15. Datz C., Cramp M., Haas T., et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut. 44:1999;563-567.
16. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 34:2001;730-739.
17. Benhamou Y, Bochet M, Di Martino V, et al, for the Multivirc Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30: 1054-1058.
18. Soriano V., Sulkowski M., Bergin C., et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV international panel. AIDS. 16:2002;813-828.
19. Wiley T.E., McCarthy M., Breidi L., McCarthy M., Layden T.J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 28:1998;805-809.
20. Bissell D.M. Sex and hepatic fibrosis. Hepatology. 29:1999;988-989.
21. Hourigan L.F., Macdonald G.A., Purdie D., et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 29:1999;1215-1219.
22. Ortiz V., Berenguer M., Rayon J.M., Carrasco D., Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 97:2002;2408-2414.
23. Gumber S.C., Chopra S.C. Hepatitis C: a multifaced disease. Review of extrahepatic manifestations. Ann Intern Med. 123:1995;615-620.
24. Cacoub P, Poynard T, Ghillani P, et al, for the Multivirc Group. Extrahepatic manifestations in patients with chronic hepatitis C. Arthritis Rheum 1999; 42: 2204-2212.
25. El-Serag H.B., Hampel H., Yeh C., Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 36:2002;1439-1445.
26. El-Serag H.B., Kunik M., Richardson P., Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 123:2002;476-482.
27. Pawlotsky J.M. Use and interpretation of virological tests for hepatitis C. Hepatology. 36:2002;S65-S73.
28. Poynard T., Marcellin P., Lee S., et al. Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
29. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 339:1998;1485-1492.
30. Poynard T., McHutchison J., Goodman Z., Ling M.H., Albrecht J. Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology. 31:2000;211-218.
31. Lindsay K., Trepo C., Heintges T., et al. A randomised, double blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 34:2001;395-403.
32. Zeuzem S., Feinman S.V., Rasenack J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 343:2000;1673-1680.
33. Heathcote E.J., Shiffman M.L., Cooksley W.G.E., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 343:2000;1673-1680.
34. Manns M.P., McHutchison J.G., Gordon S.C., et al. PEG-interferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965.
35. Fried M., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:2002;975-982.
36. Hadziyannis S.J., Cheinquer H., Morgan T., et al. Peginterferon alfa-2a (40kD) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomised, double-blind multicentre study examining effect of duration of treatment and RBV dose. J Hepatol. 36:(suppl):2002;3.
37. Heydtmann M., Shields P., McCaughan G., Adams D. Cytokines and chemokines in the immune response to hepatitis C infection. Curr Opin Infect Dis. 14:2001;279-287.
38. Wedemeyer H., He X.S., Nascimbeni M., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 169:2002;3447-3458.
39. Takaki A., Wiese M., Maertens G., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 6:2000;578-582.
40. Pawlotsky J.M., Bouvier-Alias M., Hezode C., Darthuy F., Remire J., Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology. 32:2000;654-659.
41. Castillo I., Pardo M., Bartolome J., et al. Occult hepatitis C infection in patients with persistently abnormal liver function tests of unknown etiology. Hepatology. 67:2003;187A.
42. Dienstag J.L. The role of liver biopsy in chronic hepatitis C. Hepatology. 36:(suppl):2002;S152-S160.
43. The French METAVIR cooperative study group. Intraobserver and interobserver variation in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
44. Alberti A., Noventa F., Benvegnu L., Boccato S., Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med. 137:2002;961-964.
45. Maharaj B., Maharaj R.J., Leary W.P., et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1:1986;523-525.
46. Regev A., Behro M., Jeffers L., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 97:2002;2614-2618.
47. Bedossa P., Dargère B., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 38:2003;1449-1457.
48. Poynard T., Ratziu V., Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol. 14:2000;543-548.
49. Gebo K.A., Herlong H.F., Torbenson M.S., et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 36:(suppl):2002;S161-S172.
50. Afdhal N.H. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology. 37:2003;972-974.
51. Corrao G., Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology. 27:1998;914-919.
52. Hickman I.J., Clouston A.D., Macdonald G.A., et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 51:2002;89-94.
53. Myers RP, Regimbeau C, Thevenot T, et al. Interferon for interferon-naive patients with chronic hepatitis C(Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software, 2002.
54. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 122:2002;1303-1313.
55. Sobesky R., Mathurin P., Charlotte F., et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology. 116:1999;378-386.
56. Shiffman M.L., Hofmann C.M., Melissa J., et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 117:1999;1164-1172.
57. Shiratori Y., Imazeki F., Moriyama M., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 132:2000;517-524.
58. Siebert U, Sroczynski G, Rossol S, et al, for the GEMHO Group, IHIT Group. Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-432.
59. Hinrichsen H., Benhamou Y., Reiser M., et al. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology. 36:2002;379A.
60. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature (Published online Oct 26; DOI 10.1038/nature02099).
61. Kjaergard L.L., Krogsgaard K., Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ. 323:2001;1151-1155.
62. Schalm SW, Weiland O, Hansen BE, et al, for the Eurohep Study Group for Viral Hepatitis. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999; 117: 408-413.
63. Camma C., Giunta M., Andreone P., Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 34:2001;593-602.
64. Nishiguchi S., Kuroki T., Nakatani S., et al. Randomized trial of effects of Interferon alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346:1995;1051-1055.
65. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 131:1999;174-181.
66. Baffis V., Shrier I., Sherker A.H., Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med. 131:1999;696-701.
67. Bruno S., Battezzati P.M., Bellati G., et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol. 34:2001;748-755.
68. Yoshida H., Arakawa Y., Sata M., et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 123:2002;483-491.
69. Soriano V., Sulkowski M., Bergin C., et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS. 16:2002;813-828.
70. Benhamou Y, Bochet M, Di Martino V, et al, for the Multivirc Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30: 1054-1058.
71. Benhamou Y., Di Martino V., Bochet M., et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 34:2001;283-287.
72. Zylberberg H., Benhamou Y., Lagneaux J.L., et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut. 47:2000;694-697.
73. Thevenot T., Regimbeau C., Ratziu V., Leroy V., Opolon P., Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: update. J Viral Hepat ; 8. 2001:1999;48-62.
74. Poynard T, Regimbeau C, Myers RP, et al. Interferon for acute hepatitis C (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software 2002.
75. Jaeckel E., Cornberg M., Wedemeyer H., et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 345:2001;1452-1457.